Independent fund research. Built on SEC filings.

How we research funds

ETF · Leveraged & Inverse · Direxion

Direxion Daily Healthcare Bull 3X ETF (CURE)

Ticker CURE · · Holdings as of Jul 31, 2026

Expense ratio
0.94%$94/yr per $10k
5-yr return
+8.6%annualized
1-yr return
+22.9%as of Dec 2025
Net assets
$171.7Mall share classes
Holdings
67

Bottom line

Is CURE a good fund? The bottom line

CURE is an actively managed leveraged & inverse ETF from Direxion.

It charges 0.94% — about $94 a year on every $10,000 invested, cheaper than 88% of leveraged & inverse funds we track.

It returned +22.9% over one year, +8.6% a year over five years, +13.6% a year over ten (as of Dec 31, 2025, per its prospectus).

With $172 million in net assets and 67 holdings, its largest position is Dreyfus (18.8%) and the top 10 make up 76.7% of the portfolio.

What stands out

  • Low cost: cheaper than 88% of leveraged & inverse peers
  • 5-year return beat 81% of category peers

What to watch

  • Concentrated: top 10 holdings are 76.7% of assets

Updated Nov 19, 2026

What CURE invests in

The Fund seeks daily investment results, before fees and expenses, of 300% of the daily performance of the Index. The Fund does not seek to achieve its stated investment objective for a period of time different than a trading day.

"The Index is provided by S&P Dow Jones Indices (the Index Provider) and includes domestic companies from the healthcare sector, which includes the following industries: pharmaceuticals; health care equipment and supplies; health care providers and services; biotechnology; life sciences tools and services; and health care technology. The Index is one of eleven Select Sector Indexes developed and maintained in accordance with the following criteria: (1) each of the component securities in the Index is a constituent of the S&P 500 Index and (2) the Index is calculated by the Index Provider based on a proprietary modified market capitalization methodology which means that modifications may be made to the market capitalization weights of single stock concentrations in order to conform to the requirements of the Internal Revenue Code of 1986, as amended. As of December 31, 2025, the Index…

From the fund's prospectus (filed Mar 3, 2026).

CURE performance

Fund calendar-year total returns, 2016–2025 2016: −17.4%; 2017: +69.3%; 2018: +2.9%; 2019: +55.9%; 2020: +5.1%; 2021: +87.4%; 2022: −20.4%; 2023: −9.8%; 2024: −8.5%; 2025: +22.9% −17% 2016 +69% 2017 +3% 2018 +56% 2019 +5% 2020 +87% 2021 −20% 2022 −10% 2023 −9% 2024 +23% 2025
Fund gain (+) Fund loss (−)
Average annual total returns
1 yr5 yr10 yr
CURE+22.9%+8.6%+13.6%
Leveraged & Inverse median−7.7%−11.8%−13.5%

Source: Fund prospectus, as of Dec 31, 2025

Full CURE performance history →

What CURE costs

On a $10,000 investment, CURE's 0.94% expense ratio costs about $94 a year. The prospectus estimates $1,155 in total costs over 10 years (assuming 5% annual returns). The median leveraged & inverse fund charges 1.31%.

See the full CURE fee table →

CURE top 10 holdings

#Holding% of fund
1Dreyfus18.79%
2Eli Lilly & Company LLY10.41%
3N/a8.28%
4Goldman Sachs Liq Es Fd A8.19%
5Goldman Financial7.51%
6Johnson & Johnson JNJ7.07%
7Abbvie Inc ABBV5.08%
8Unitedhealth Group Inc UNH4.31%
9Merck & Company Inc MRK3.68%
10N/a3.34%

Source: SEC Form N-PORT, period ended Jul 31, 2026

The top 10 make up 76.7% of the fund. See all top 25 holdings and asset mix →

Alternatives to CURE

More funds like CURE →

CURE FAQ

What is the expense ratio of CURE?
CURE's expense ratio is 0.94%, which works out to about $94 a year for every $10,000 invested. The prospectus estimates total costs of $1,155 over 10 years on a $10,000 investment (assuming 5% annual returns).
Is CURE a good investment?
It depends on your goals, but the data points to: low cost: cheaper than 88% of leveraged & inverse peers; 5-year return beat 81% of category peers; concentrated: top 10 holdings are 76.7% of assets. This is general information, not personalized advice.
What does CURE hold?
CURE's largest holdings are Dreyfus (18.8%), Eli Lilly & Company (10.4%), N/a (8.3%), Goldman Sachs Liq Es Fd A (8.2%), Goldman Financial (7.5%). It holds 67 positions in total as of Jul 31, 2026 (SEC Form N-PORT).
What is CURE's 5-year return?
CURE returned +8.6% a year over the five years ending Dec 31, 2025, and +13.6% a year over ten years. Past performance does not guarantee future results.
Who manages CURE?
CURE is offered by Direxion through Direxion Shares ETF Trust.